Micellar paclitaxel in the treatment of patients with tumors of the female reproductive system
Background. Treatment of patients with advanced cancers of the female reproductive system is very challenging. The most common treatment scheme for such patients includes paclitaxel 135—175 mg/m2 + carboplatin AUC 5—6 or cisplatin 75 mg/m2. However, lengthy treatment with this regimen is limited by...
Main Authors: | A. G. Kedrova, S. E. Krasilnikov, D. A. Astakhov, V. V. Kosyy |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2019-11-01
|
Series: | Опухоли женской репродуктивной системы |
Subjects: | |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/661 |
Similar Items
-
Paclitaxel Has a Reduced Toxicity Profile in Healthy Rats After Polymeric Micellar Nanoparticle Delivery
by: Lu J, et al.
Published: (2023-01-01) -
Effect of high-dose polymeric nanoparticle micellar paclitaxel on improved progression-free survival in patients with optimally resected stage III or IV high-grade carcinoma of the ovary: a prospective cohort study with historical controls
by: Soo Jin Park, et al.
Published: (2024-02-01) -
Histopathological Efficacy of Docetaxel Versus Paclitaxel As First Line Chemotherapy for Epithelial Ovarian Carcinoma
by: Tayyup Şimşek, et al.
Published: (2008-12-01) -
Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancersurgery
by: Sally Mullany, et al.
Published: (2020-11-01) -
New and Old Genes Associated with Primary and Established Responses to Paclitaxel Treatment in Ovarian Cancer Cell Lines
by: Monika Świerczewska, et al.
Published: (2018-04-01)